This article was originally published in The Gray Sheet
FDA expects to issue a guidance on labeling for devices containing di(2-ethylhexyl)phthalate (DEHP) "in the very near future," according to an April 5 letter from the agency to Health Care Without Harm denying the group's Oct. 5, 2001 petition for reconsideration. In September 2001, the agency denied HCWH's initial citizen petition requesting that all polyvinyl chloride medical devices be required to bear warning labels and that FDA encourage the development of alternatives to PVC (1"The Gray Sheet" Sept. 10, 2001, p. 18). In the April letter, FDA maintains that HCWH failed to satisfy the criteria required for the agency to grant a petition for reconsideration...
You may also be interested in...
FDA will examine the safety and availability of alternatives to devices containing the plasticizer di-2-ethylhexyl-phthalate (DEHP) before considering a risk management strategy.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.